International Markets for Vascular Access Site Closure Devices — June 2016

Cardiovascular diseases (CVDs) are the leading causes of death throughout the world.  Based on Datamonitor Healthcare estimates, approximately 500 million CVD-related cases occurred in the United States (U.S.), China, Japan, and the five major countries of Europe (France, Germany, Italy, Spain, and the United Kingdom [U.K.]).  According to the World Health Organization, approximately 17 million people die from cardiovascular diseases (CVDs) every year, with over 75% of all CVD-related deaths occurring in low- and middle-income countries. The number of global CVD-related procedures (diagnostic and therapeutic) continues to increase as more people around the world gain access to improved therapies for the diagnosis and management of CVDs.  The creation of an arteriotomy, or access site, in the vasculature is central to all interventional cardiology procedures.  Post-procedure, the risk of bleeding and/or complications at the vascular access site becomes a major obstacle to early patient discharge.  Vascular access site closure devices, or vascular closure devices (VCDs), are utilized to achieve hemostasis and prevent complications (e.g., bleeding and hematoma formation). Over the next five years, the global market for VCDs is expected to experience high, single digit annual growth. By 2020, the total sales attributable to VCDs are anticipated to exceed $1.3 billion globally.

For the purpose of this analysis, region/country-specific market and competitive analyses will focus on the United States (U.S.), Europe, Japan, and the Rest of the world (RoW).  The U.S. remains the largest market in terms of total VCD sales, followed by Europe and Asia-Pacific.